HUTCHMED (China) (HCM) Cash from Investing Activities (2018 - 2021)
HUTCHMED (China)'s (HCM) quarterly Cash from Investing Activities came in at -$315.9 million in Q2 2021, down 665.3% year-on-year from $55.9 million in Q2 2020, and down 297.41% on a QoQ basis from $160.0 million in Q1 2021.
HUTCHMED (China) (HCM) Cash from Investing Activities (2018 - 2021) Analysis & Trends
HUTCHMED (China) (HCM) has 4 years of Cash from Investing Activities data on file, last reported at -$315.9 million in Q2 2021.
- On a quarterly basis, Cash from Investing Activities fell 665.3% year-over-year to -$315.9 million in Q2 2021; TTM through Jun 2021 was -$295.0 million, a 281.98% decrease from a year earlier, with the FY2025 full-year figure at -$29.4 million, up 69.38% from the prior year.
- Cash from Investing Activities for Q2 2021 stood at -$315.9 million, down from $160.0 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for HCM reached as high as $160.0 million in Q1 2021 and fell as low as -$315.9 million in Q2 2021.
- Historically, Cash from Investing Activities has averaged -$11.0 million across 4 years, with a median of $19.0 million in 2019.
- Across the five-year window, Cash from Investing Activities soared 299.29% in 2019 and sank 665.3% in 2021, its largest moves.
- Year by year, Cash from Investing Activities stood at -$15.3 million in 2018, then soared by 193.2% to $14.2 million in 2019, then slumped by 390.3% to -$41.3 million in 2020, then sank by 665.3% to -$315.9 million in 2021.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were -$315.9 million in Q2 2021, $160.0 million in Q1 2021, and -$41.3 million in Q2 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.69 Bn | 87.82 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.57 Bn | 30.63 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.52 Bn | 23.46 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 23.08 Bn | 20.93 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 22.43 Bn | 22.43 Bn | - | - |
| 7 | Viatris | 20.23 Bn | 18.42 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.78 Bn | 16.46 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn | -60.00 Mn |
| 10 | HUTCHMED (China) | 9.57 Bn | 9.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -315.92 Mn |
| Jun 30, 2021 | -315.92 Mn |
| Mar 31, 2021 | 160.04 Mn |
| Mar 31, 2021 | 160.04 Mn |
| Jun 30, 2020 | -41.28 Mn |
| Jun 30, 2020 | -41.28 Mn |
| Mar 31, 2020 | -97.84 Mn |
| Mar 31, 2020 | -97.84 Mn |
| Dec 31, 2019 | 14.22 Mn |
| Dec 31, 2019 | 14.22 Mn |
| Sep 30, 2019 | 47.67 Mn |
| Sep 30, 2019 | 47.67 Mn |
| Jun 30, 2019 | 23.76 Mn |
| Jun 30, 2019 | 23.76 Mn |
| Mar 31, 2019 | 33.38 Mn |
| Mar 31, 2019 | 33.38 Mn |
| Dec 31, 2018 | -15.26 Mn |
| Dec 31, 2018 | -15.26 Mn |
| Sep 30, 2018 | 43.22 Mn |
| Sep 30, 2018 | 43.22 Mn |